EQT Healthcare Growth to acquire Europa Biosite, a distributor of over ten million high-quality life science reagents to academic and biopharma researchers across Europe...
BOSTON and OSLO, Norway, July 3, 2025 /PRNewswire/ -- Volta Labs, Inc., a leading genomics applications company, announced today the expansion of its commercial...
Lab will support semi-permanent setups, offering more flexibility and capacity for customers requiring expanded test services
CHANDLER, Ariz., July 2, 2025 /PRNewswire/ -- VIAVI Solutions...
BEIJING, July 2, 2025 /PRNewswire/ -- HyperStrong, a global leader in energy storage system integration, signed a strategic Memorandum of Understanding (MoU) with Singapore-based...
Over 40 Years of Dedicated Partnership and Growth in Singapore's Transformation Journey
SINGAPORE, July 2, 2025 /PRNewswire/ -- Johnson Controls (NYSE: JCI), the global leader for smart,...
Over $100,000 in financial and technology grants awarded globally to support educators and innovation
NEW YORK, July 1, 2025 /PRNewswire/ -- Echo360, the global leader in transformative...
HYDERABAD, India, July 1, 2025 /PRNewswire/ -- IBSAT is an online aptitude test conducted by The ICFAI Foundation for Higher Education (The IFHE), Hyderabad...
Seeks Damages and Injunctions to Restore its Exclusive Patent Rights
TEMPLE, Texas, June 30, 2025 /PRNewswire/ -- Xockets, Inc., a Texas-based pioneer and the inventor...
The continuous improvement of Shanghai Electric's brand value is due to a resilient long-term development structure with a strong focus on ESG management.
SHANGHAI, June 30,...
BOSTON, June 30, 2025 (GLOBE NEWSWIRE) -- PathAI, a global leader in artificial intelligence (AI) and digital pathology solutions, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for AISight® Dx*—its digital pathology image management system—for use in primary diagnosis in clinical settings. Building on the initial 510(k) clearance for AISight Dx(Novo) in 2022, this latest milestone underscores the platform’s continuous innovation and PathAI’s commitment to delivering enhanced capabilities as the product evolves.